Tag Archives: BIO Investor Forum

#BIF2012 Company Snapshot: ContraFect Corporation

ContraFect

The BIO Investor Forum is fast approaching! Below you’ll find our first Company Snapshot of one of the event’s presenting companies, ContraFect Corporation. Continue reading to learn more about ContraFect’s product, their strategies, and what you can expect from their company in the coming months. Company Snapshot What is your company’s lead product or technology? ContraFect is a private company developing biotherapeutics for resistant, life threatening infections. Our lead compound, CF-301, is a bacteriophage lysin, Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , ,

2012 BIO Investor Forum: Looking Ahead to Investment Opportunities

partnering1

The biggest biotech news out of Washington in recent months was the Jumpstart Our Business Startups (JOBS) Act, which passed Congress overwhelmingly and was signed into law by President Obama in April.  For those not familiar, the JOBS Act creates a new category of issuers, called “emerging growth companies” (EGCs), which is defined as newly public companies with than $1 billion in annual revenues and a public float below $700 million. EGCs are given a Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

2012 Fall Event Preview

agenda

The 2012 BIO International Convention, the global event for biotechnology, held at the Boston Convention & Exhibition Center in Boston, Mass., wrapped this June. The event hosted a record 25,291 partnering meetings and highlighted a broad array of top-level speakers addressing critical global challenges and the top issues in biotechnology. Hosted by the Biotechnology Industry Organization (BIO), the event drew 16,505 industry leaders from 49 states and 65 countries. See what BIO President and CEO Jim Greenwood Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

Opportunity or Apocalypse? Prophecies for 2012

BIF Closing Plenary

On day two of the BIO Investor Forum in San Francisco, Calif., attendees were eager to participate in the Closing Plenary. Historically, this session draws the biggest crowd of the conference and this year was no exception. Speaking to a packed audience, with standing room only, the panelists engaged in a lively discussion about the state of the industry and what is in the cards for 2012. Both Bryan Roberts, PhD, Partner, Venrock and Matthew Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,

Beyond the ABCs of ADCs

Antibody

The recent FDA approval of Seattle Genetics’ antibody, Adcetris, has cast the spotlight on Antibody Drug Conjugates (ADC), leaving experts to contemplate whether this is the peak for ADCs. If history has its say though, the spotlight won’t be flickering anytime soon. Experts in this specialized antibody field discussed the latest developments and lessons of bringing ADCs through the clinic at this week’s 10th Annual BIO Investor Forum. Antibody drug conjugates hold enormous potential for treating Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,